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COVID-19 and IBD drugs: should we 
change anything at the moment?
Charlie W Lees   ,1,2 Peter M Irving   ,3 Laurent Beaugerie4,5
The COVID-19 pandemic has raised ques-
tions about the management of people 
with inflammatory bowel disease (IBD).1 
To date, there have been over 43 million 
confirmed cases of COVID-19 globally, 
including over 1.1 million deaths (https:// 
COVID- 19. who. int). What have we learnt 
about the risks of SARS- CoV-2 infection 
in patients with IBD and is there any 
evidence to support a change in IBD 
management?
Established risk factors for poor 
COVID-19 outcomes are older age, male 
sex, obesity, non- white ethnicity, type 2 
diabetes, social deprivation and a range 
of comorbidities (respiratory disease, 
cardiovascular disease, stroke, malignancy 
and liver disease).2 Based on prior knowl-
edge and early observations from China 
and Italy, patients with IBD felt to be at 
higher risk included older patients with 
comorbidities, patients on higher doses 
of systemic corticosteroids and patients 
with active disease.1 3 However, they were 
generally advised not to stop IBD treat-
ment in order to minimise the risk of flare, 
steroid prescription and hospitalisation 
during the pandemic.1
The SECURE- IBD Registry was set up 
to collect data on confirmed SARS- CoV-2 
infections in people with IBD to address 
the urgent need for information guiding 
decisions about drug therapy during a 
time of great uncertainty. This physician- 
reported registry has accrued over 2700 
cases to date (https:// covidibd. org/ 
current- data/). An initial analysis of 521 
patients reported an association between 
corticosteroids and adverse COVID-19 
outcomes.4 Ungaro and colleagues now 
report an expanded analysis on the first 
1439 cases.5 These cases were 34.5% 
from the USA, 51.4% male individuals 
and 82.1% white. Overall, 38.5% of 
patients were on anti- tumour necrosis 
factor (TNF) therapy and 30.6% were 
taking a 5- ASA preparation. The primary 
outcome measure of severe COVID-19 
disease was a composite of intensive care 
unit (ICU) admission, mechanical ventila-
tion or death. This endpoint was met in 
112 of 1439; 79% of those with a severe 
COVID-19 outcome were over 50 years 
of age. With only 24 events in those under 
50 years of age, it is difficult to draw too 
many conclusions about younger adults.
The major finding was of an increased 
risk of severe COVID-19 outcomes 
in patients taking thiopurines.5 Using 
anti- TNF monotherapy as a reference 
arm, thiopurine monotherapy and 
anti- TNF plus thiopurine combination 
therapy were both associated with worse 
outcomes (ORs of 4.08 and 4.01, respec-
tively). On face value, these are clinically 
impactful results. However, there are 
several important limitations that require 
detailed exploration.
The most important consideration is 
around the physician- reporting nature 
of the registry. This may introduce over- 
reporting of cases in closer follow- up 
(biologic- treated patients with IBD), 
memory bias (over- reporting of serious 
outcomes) and confirmation bias (over- 
reporting of cases that fit a predefined 
viewpoint: eg, thiopurines are bad; 
biologics are good). There is also a risk of 
under- reporting some cases due to a lack 
of notification; it is possible that gastroen-
terologists are less likely to be made aware 
of patients with stable IBD who are not 
on biologics with non- severe COVID-19, 
compared with a patient who is taking a 
biologic or is admitted to the ICU.
In addition, specific to COVID-19, 
there is a danger of testing bias. This 
cohort was accumulated exclusively 
during the first wave when testing for 
SARS- CoV-2 was limited (13 March to 
9 June 2020). Patients in the community 
with mild symptoms were unlikely to be 
tested. It is possible that stable patients 
taking 5- ASA or thiopurines would only 
have attended hospital if they had severe 
COVID-19, at which point they would be 
tested. However, patients with active IBD 
(who are more likely to be taking steroids) 
or attending for the administration of a 
biologic, who had mild COVID-19 symp-
toms would likely have been tested.
It is established that thiopurines are 
known to increase the risk of viral infec-
tions more than anti- TNFs do.6 In partic-
ular, they promote severe forms of primary 
infection/reactivation of Epstein- Barr virus 
(EBV),7 8 cytomegalovirus (CMV)7 and 
varicella zoster virus9 infection. However, 
there is less evidence that thiopurines also 
promote severe infections of the upper 
respiratory tract. In a tertiary cohort with 
15 000 patient- years of follow- up, no 
case of fatal or hospitalisation- requiring 
influenza was reported.7 Furthermore, in 
the nationwide Danish database, while 
patients with IBD were more prone than 
matched controls to develop influenza and 
serious influenza requiring hospitalisation, 
exposure to thiopurines did not increase 
this risk.10 However, the lack of any prior 
immunity to SARS- CoV-2, a completely 
novel respiratory virus, requires caution in 
extrapolating any further from the influ-
enza data.
While the increased risk of severe 
COVID-19 in patients exposed to mono-
therapy with thiopurines versus those 
exposed to monotherapy with anti- 
TNFs may be explained by a deleterious 
effect of thiopurines, it may also relate 
to a beneficial effect of anti- TNFs. In a 
randomised controlled trial by Abraham 
et al,11 patients with severe sepsis were 
randomly assigned to receive an infusion 
of placebo, infliximab 7.5 mg/kg or inflix-
imab 15 mg/kg. There was a significant 
reduction in mortality (40%) at day 3 in 
the subgroup of patients with septic shock. 
Indeed, phase 2 trials of infliximab and 
adalimumab in COVID-19 are planned/
ongoing (https://www. clinicaltrials. gov, 
NCT04425538).12
Risks and/or benefits of drug therapy 
may also be confounded by disease activity. 
Both systemic and intestinal inflammation 
in IBD promote the replication of EBV 
and CMV,13 and clinically active IBD at 
the onset of viral infection is a strong and 
independent risk factor for serious infec-
tions.7 It is possible that patients exposed 
to combination therapy represent a more 
severe cohort who are more prone to 
have uncontrolled IBD (particularly severe 
perianal Crohn’s disease) compared with 
patients treated with anti- TNF mono-
therapy. If this is real, the particular severity 
of COVID-19 in patients receiving the 
combination of thiopurines and anti- TNF 
compared with those given monotherapy 
with anti- TNFs could be at least partially 
attributed to the severity of inflammation.
The findings reported by Ungaro and 
colleagues are valuable and welcomed. 
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Commentary
However, we need robust data to confirm 
or disprove the authors’ conclusions based 
on the SECURE- IBD registry. Nation-
wide medico- administrative databases can 
provide complete data on the incidence 
of severe COVID-19 and drug expo-
sures, although the adjustment for disease 
activity is partial. Publications derived 
from such databases are expected soon.
Based on the currently available data, 
we do not advocate withdrawing thiopu-
rines in younger adults without other risk 
factors. In older and higher risk patients, 
the totality of risk and benefit of thiopu-
rine therapy should be considered. This 
requires taking into account not only 
COVID-19 but also well- known risks such 
as lymphoma, as well as the limited benefit 
of thiopurine monotherapy in Crohn’s 
disease.14 15 It is important, however, to 
remember that there is a significant risk 
of disease flare on withdrawal of thio-
purine monotherapy and an increased 
risk of immunogenicity and hence drug 
failure where patients are on combination 
therapy. Our recommendation, therefore 
is not to deviate substantially from current 
guidance based on these new data alone 
and to continue to consider combination 
therapy, especially for high- risk pheno-
types such as fistulising Crohn’s disease, 
while we await other studies.
Twitter Charlie W Lees @charlie_lees
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